Aimee O. Hersh
YOU?
Author Swipe
View article: “There’s so much to be done”: a qualitative study to elucidate research priorities in childhood-onset systemic lupus erythematosus
“There’s so much to be done”: a qualitative study to elucidate research priorities in childhood-onset systemic lupus erythematosus Open
OBJECTIVE: There is a pressing need for high-quality, comprehensive research to describe the natural history, best treatments, access to care and disparities in care for patients with childhood-onset SLE (cSLE). Building on a previously pu…
View article: Disease activity trajectories in paediatric lupus and associations with socioeconomic factors and patient-reported pain
Disease activity trajectories in paediatric lupus and associations with socioeconomic factors and patient-reported pain Open
Objective Using data from participants with paediatric SLE (pSLE) in the Childhood Arthritis and Rheumatology Research Alliance Registry, we aimed to: (1) describe 2-year disease activity trajectories, measured by the SLE Disease Activity …
View article: 2024 American College of Rheumatology (<scp>ACR</scp>) Guideline for the Screening, Treatment, and Management of Lupus Nephritis
2024 American College of Rheumatology (<span>ACR</span>) Guideline for the Screening, Treatment, and Management of Lupus Nephritis Open
Objective The objective is to provide evidence‐based and expert guidance for the screening, treatment, and management of lupus nephritis. Methods The Core Team developed clinical questions for screening, treatment, and management of lupus …
View article: Patient and parent perspectives on an academic rheumatology transition clinic
Patient and parent perspectives on an academic rheumatology transition clinic Open
A difficulty in defining a successful transfer is how to simultaneously integrate the perspective and needs of the patient and parents. This research shows that the values of patients and their parents generally align. However, there are i…
View article: Racial Disparities and Achievement of the Low Lupus Disease Activity State: A <scp>CARRA</scp> Registry Study
Racial Disparities and Achievement of the Low Lupus Disease Activity State: A <span>CARRA</span> Registry Study Open
Objective Differential disease control may contribute to racial disparities in outcomes of childhood‐onset systemic lupus erythematosus (cSLE). We evaluated associations of race and individual‐ or neighborhood‐level social determinants of …
View article: 1301 Factors driving disparities in glucocorticoid exposure among children with SLE in the CARRA registry
1301 Factors driving disparities in glucocorticoid exposure among children with SLE in the CARRA registry Open
Background Differential glucocorticoid exposure and related toxicity may exacerbate racial and ethnic disparities in lupus-related organ damage and mortality. Pediatric-onset systemic lupus erythematosus (pSLE) confers an even greater life…
View article: Shared genomic segments analysis identifies MHC class I and class III molecules as genetic risk factors for juvenile idiopathic arthritis
Shared genomic segments analysis identifies MHC class I and class III molecules as genetic risk factors for juvenile idiopathic arthritis Open
View article: Correction: Engaging patients and parents to improve mental health intervention for youth with rheumatological disease
Correction: Engaging patients and parents to improve mental health intervention for youth with rheumatological disease Open
View article: Efficacy and Safety of Pharmacokinetically-Driven Dosing of Mycophenolate Mofetil for the Treatment of Pediatric Proliferative Lupus Nephritis-A Double-Blind Placebo Controlled Clinical Trial (The Pediatric Lupus Nephritis Mycophenolate Mofetil Study).
Efficacy and Safety of Pharmacokinetically-Driven Dosing of Mycophenolate Mofetil for the Treatment of Pediatric Proliferative Lupus Nephritis-A Double-Blind Placebo Controlled Clinical Trial (The Pediatric Lupus Nephritis Mycophenolate Mofetil Study). Open
The Pediatric Lupus Nephritis Mycophenolate Mofetil (PLUMM) study will provide a thorough evaluation of the PK of MMF in pediatric LN patients, yielding a head-to-head comparison of MMFBSA and MMFPK for both safety an…
View article: Prevalence of tissue transglutaminase antibodies and IgA deficiency are not increased in juvenile idiopathic arthritis: a case-control study
Prevalence of tissue transglutaminase antibodies and IgA deficiency are not increased in juvenile idiopathic arthritis: a case-control study Open
Background The prevalence of Celiac Disease (CD) in Juvenile Idiopathic Arthritis (JIA) has been reported to be 0.1–7% in various small studies. As a result of the limited number of research and their inconclusive results there are no clea…
View article: Disease Course, Treatments, and Outcomes of Children With Systemic Juvenile Idiopathic Arthritis–Associated Lung Disease
Disease Course, Treatments, and Outcomes of Children With Systemic Juvenile Idiopathic Arthritis–Associated Lung Disease Open
Objective Systemic juvenile idiopathic arthritis–associated lung disease (SJIA‐LD) is a life‐threatening disease complication. Key questions remain regarding clinical course and optimal treatment approaches. The objectives of the study wer…
View article: Prevalence of tissue Transglutaminase Antibodies and IgA deficiency are not increased in Juvenile Idiopathic Arthritis: A case-control study.
Prevalence of tissue Transglutaminase Antibodies and IgA deficiency are not increased in Juvenile Idiopathic Arthritis: A case-control study. Open
Background: The prevalence of Celiac Disease (CD) in Juvenile Idiopathic Arthritis (JIA) has been reported to be 0.1% to 7% in various small studies. As a result of the limited number of research and their inconclusive results there are no…
View article: First-line options for systemic juvenile idiopathic arthritis treatment: an observational study of Childhood Arthritis and Rheumatology Research Alliance Consensus Treatment Plans
First-line options for systemic juvenile idiopathic arthritis treatment: an observational study of Childhood Arthritis and Rheumatology Research Alliance Consensus Treatment Plans Open
Background The Childhood Arthritis and Rheumatology Research Alliance (CARRA) developed consensus treatment plans (CTPs) to compare treatment initiation strategies for systemic juvenile idiopathic arthritis (sJIA). First-line options for s…
View article: 622 Childhood-onset SLE Outcomes in the CARRA Lupus Registry
622 Childhood-onset SLE Outcomes in the CARRA Lupus Registry Open
Objective This study aims to describe the demographic features, cumulative clinical manifestations, and treatments in a large childhood-onset (cSLE) cohort in the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry. Thi…
View article: <scp>Childhood‐Onset</scp> Lupus Nephritis in the Childhood Arthritis and Rheumatology Research Alliance Registry: <scp>Short‐Term</scp> Kidney Status and Variation in Care
<span>Childhood‐Onset</span> Lupus Nephritis in the Childhood Arthritis and Rheumatology Research Alliance Registry: <span>Short‐Term</span> Kidney Status and Variation in Care Open
Objective The goal was to characterize short‐term kidney status and describe variation in early care utilization in a multicenter cohort of patients with childhood‐onset systemic lupus erythematosus (cSLE) and nephritis. Methods We analyze…
View article: Evaluation of Serious Infection in Pediatric Patients with Low Immunoglobulin Levels Receiving Rituximab for Granulomatosis with Polyangiitis or Microscopic Polyangiitis
Evaluation of Serious Infection in Pediatric Patients with Low Immunoglobulin Levels Receiving Rituximab for Granulomatosis with Polyangiitis or Microscopic Polyangiitis Open
View article: “There’s so much to be done”: a qualitative study to elucidate research priorities in childhood-onset systemic lupus erythematosus
“There’s so much to be done”: a qualitative study to elucidate research priorities in childhood-onset systemic lupus erythematosus Open
Objective There is a pressing need for high-quality, comprehensive research to describe the natural history, best treatments, access to care and disparities in care for patients with childhood-onset SLE (cSLE). Building on a previously pub…
View article: Use of EuroLupus Cyclophosphamide Dosing for the Treatment of Lupus Nephritis in Childhood-onset Systemic Lupus Erythematosus in North America
Use of EuroLupus Cyclophosphamide Dosing for the Treatment of Lupus Nephritis in Childhood-onset Systemic Lupus Erythematosus in North America Open
Objective. Childhood-onset systemic lupus erythematosus (cSLE) has higher rates of lupus nephritis (LN) than adult-onset SLE, often requiring intensive immunosuppression. This study examined North American practices and preferences for the…
View article: A novel transition clinic structure for adolescent and young adult patients with childhood onset rheumatic disease improves transition outcomes
A novel transition clinic structure for adolescent and young adult patients with childhood onset rheumatic disease improves transition outcomes Open
Background The transition of health care from Pediatric to Adult providers for adolescents and young adults with chronic disease is associated with poor outcomes. Despite the importance of this transition, over 80% of these patients do not…
View article: 1110 Overview of the childhood systemic lupus erythematosus (cSLE) cohort in the CARRA registry
1110 Overview of the childhood systemic lupus erythematosus (cSLE) cohort in the CARRA registry Open
Background The Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry is a multi-center, observational registry that collects demographic, clinical, and provider- and patient-reported data from patients with pediatric-onse…
View article: Principles of pediatric lupus nephritis in a prospective contemporary multi-center cohort
Principles of pediatric lupus nephritis in a prospective contemporary multi-center cohort Open
Lupus nephritis (LN) is a life-threatening manifestation of systemic lupus erythematosus (SLE) and is more common in children than adults. The epidemiology and management of childhood-onset SLE (cSLE) have changed over time, prompting the …
View article: Phase <scp>IIa</scp> Global Study Evaluating Rituximab for the Treatment of Pediatric Patients With Granulomatosis With Polyangiitis or Microscopic Polyangiitis
Phase <span>IIa</span> Global Study Evaluating Rituximab for the Treatment of Pediatric Patients With Granulomatosis With Polyangiitis or Microscopic Polyangiitis Open
Objective To assess the safety, tolerability, pharmacokinetics, and efficacy of rituximab (RTX) in pediatric patients with granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA). Methods The Pediatric Polyangiitis Rituxim…
View article: Engaging patients and parents to improve mental health intervention for youth with rheumatological disease
Engaging patients and parents to improve mental health intervention for youth with rheumatological disease Open
Background Mental health disorders are common in youth with rheumatological disease yet optimal intervention strategies are understudied in this population. We examined patient and parent perspectives on mental health intervention for yout…
View article: Differences in Healthcare Transition Views, Practices, and Barriers Among North American Pediatric Rheumatology Clinicians From 2010 to 2018
Differences in Healthcare Transition Views, Practices, and Barriers Among North American Pediatric Rheumatology Clinicians From 2010 to 2018 Open
Objective Since 2010, the rheumatology community has developed guidelines and tools to improve healthcare transition. In this study, we aimed to compare current transition practices and beliefs among Childhood Arthritis and Rheumatology Re…
View article: Discontinuing adalimumab in patients with controlled juvenile idiopathic arthritis-associated uveitis (ADJUST—Adalimumab in Juvenile Idiopathic Arthritis-associated Uveitis Stopping Trial): study protocol for a randomised controlled trial
Discontinuing adalimumab in patients with controlled juvenile idiopathic arthritis-associated uveitis (ADJUST—Adalimumab in Juvenile Idiopathic Arthritis-associated Uveitis Stopping Trial): study protocol for a randomised controlled trial Open
Background Juvenile idiopathic arthritis (JIA)-associated uveitis is a chronic paediatric ocular inflammatory condition that can result in visual impairment. Adalimumab, a tumour necrosis factor (TNF)-alpha inhibitor, effectively controls …
View article: SAT0503 SERIOUS INFECTION RISK IN PEDIATRIC PATIENTS WITH LOW IMMUNOGLOBULIN LEVELS FOLLOWING RITUXIMAB TREATMENT FOR GRANULOMATOSIS WITH POLYANGIITIS (GPA) OR MICROSCOPIC POLYANGIITIS (MPA)
SAT0503 SERIOUS INFECTION RISK IN PEDIATRIC PATIENTS WITH LOW IMMUNOGLOBULIN LEVELS FOLLOWING RITUXIMAB TREATMENT FOR GRANULOMATOSIS WITH POLYANGIITIS (GPA) OR MICROSCOPIC POLYANGIITIS (MPA) Open
View article: Development of a Set of Lupus‐Specific, Ambulatory Care–Sensitive, Potentially Preventable Adverse Conditions: A Delphi Consensus Study
Development of a Set of Lupus‐Specific, Ambulatory Care–Sensitive, Potentially Preventable Adverse Conditions: A Delphi Consensus Study Open
Objective Individuals with systemic lupus erythematosus (SLE) are at high risk for infections and SLE‐ and medication‐related complications. The present study was undertaken to define a set of SLE‐specific adverse outcomes that could be pr…
View article: Research priorities in childhood-onset lupus: results of a multidisciplinary prioritization exercise
Research priorities in childhood-onset lupus: results of a multidisciplinary prioritization exercise Open
View article: 92 Engaging patients and parents to improve mental health for youth with systemic lupus erythematosus
92 Engaging patients and parents to improve mental health for youth with systemic lupus erythematosus Open
Background Mental health conditions are common in youth with systemic lupus erythematosus (SLE), yet intervention strategies are understudied. We used a patient-engaged approach to investigate the mental health needs of youth with SLE. Met…
View article: 320. PEDIATRIC OPEN-LABEL CLINICAL STUDY OF RITUXIMAB FOR THE TREATMENT OF GRANULOMATOSIS WITH POLYANGIITIS AND MICROSCOPIC POLYANGIITIS
320. PEDIATRIC OPEN-LABEL CLINICAL STUDY OF RITUXIMAB FOR THE TREATMENT OF GRANULOMATOSIS WITH POLYANGIITIS AND MICROSCOPIC POLYANGIITIS Open